arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ACADIA PHARMACEUTICALS INC

ACAD
$25.43 ▼ -0.98 (-3.73%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

ACADIA PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $4.4B
Dividend Yield
Revenue Growth 16.4%
Op. Margin 12.3%
ROIC 2.0%
FCF / Share $0.56
Trailing P/E 141.3x
Price / Book 3.4x
FCF Yield 2.2%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$307.96M
↑ +16.4%
Net Income Profit after all expenses
$31.50M
↑ +18.1%
Operating Margin Operating profit as % of sales
12.3%
↑ +813.5% 56th
FCF / Share Free cash flow per share
$0.56
↑ +47.0%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
71
Returns
93
Cash Quality
31

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters